### Learner Notification

**MED Learning Group**

**Updating Outpatient Recommendations in COVID-19 Management: Identifying Opportunities for Risk Reduction in Non-Hospitalized Patients**

**March 13 – May 9, 2023  
Various Locations**

**Acknowledgement of Financial Commercial Support**

Pfizer

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Assess the latest guideline-recommended best practices for diagnosis of COVID-19 to reduce the risk of serious clinical consequences.
2. Summarize current updates concerning appropriate use of therapeutics for COVID-19 management in high-risk outpatients based on current data.
3. Evaluate current clinical criteria for selection of appropriate patients for COVID-19 therapeutics through a shared decision-making approach.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Russie | Allen | NA |
| Rashado | Coote | NA |
| Douglas | Cox | NA |
| Lisa | Crenshaw | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Deb | Gordon | NA |
| Shyam | Kottilil | OrsoBio Inc.: Stock Shareholder |
| Morgan | Kravarik | NA |
| Christopher | Palma | NA |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)